Trial Profile
Safety of biosimilar of rituximab in Argentina: A post-marketing study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 20 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology